Melphalan: Difference between revisions

Jump to navigation Jump to search
No edit summary
 
m (Reverted edits by Annaja1L (talk) to last revision by Alexandra Almonacid E.)
Line 1: Line 1:
{{Drugbox|
#REDIRECT [[Melphalan (patient information)]]
|IUPAC_name = 2-amino-3-[4-[bis(2-chloroethyl)amino]phenyl]-<br>propanoic acid
| image=Melphalan.svg
| CAS_number=148-82-3
| ATC_prefix=L01
| ATC_suffix=AA03
| PubChem=4053
| DrugBank=APRD00118
| C = 13 | H = 18 | Cl = 2 | N = 2 | O = 2
| molecular_weight = 305.2 g/mol
| bioavailability= 25% to 89%
| metabolism = hydrolysis
| elimination_half-life=1.5 ± 0.8 hours
| excretion =  [[Kidney|Renal]], significantly metabolised
| pregnancy_AU =
| pregnancy_US =
| pregnancy_category =
| legal_status = Rx-only
| routes_of_administration= Oral, [[Intravenous therapy|intravenous]]
}}
'''Melphalan hydrochloride''' (trade name '''Alkeran''') is a [[chemotherapy]] [[medication|drug]] belonging to the class of [[nitrogen mustard]] [[alkylating antineoplastic agent|alkylating agent]]s.  It is used primarily to treat [[multiple myeloma]] and [[ovarian cancer]], and occasionally [[malignant melanoma]].  Otherwise known as L-Phenylalanine Mustard, or L-PAM, melphalan is a [[phenylalanine]] derivative of [[mechlorethamine]].  The agent was first investigated as a possible drug for use in melanoma.  It did not work, but was found to be of use in myeloma.
 
==Administration==
Oral or intravenous; dosing varies by purpose and route of administration as well as patient weight.
 
==Side effects==
Common side effects include:
*[[Nausea]] and vomiting
*[[Bone marrow]] suppression, including
**[[leukopenia|Decreased white blood cell count]] causing increased risk of [[infection]]
**[[thrombocytopenia|Decreased platelet count]] causing increased risk of bleeding
 
Less common side effects include:
*Severe allergic reactions
*Scarring of lung tissue (usually only with prolonged use)
*[[alopecia|Hair loss]]
*[[Rash]]
*[[pruritus|Itching]]
 
[[Category: chemotherapeutic agents]]
{{pharma-stub}}
 
{{Chemotherapeutic agents}}
 
[[ja:メルファラン]]
[[pl:Melfalan]]

Revision as of 20:59, 19 December 2011